Jim Hollingshead - ResMed President – sleep and respiratory care business
| RMD Stock | USD 183.78 0.44 0.24% |
President
Dr. Jim R. Hollingshead, Ph.D. is President Sleep Business of the Company since July 2017. Mr. Hollingshead joined ResMed in March 2010 as vice president of strategy and business development. In August 2011, his role was expanded to include the leadership of ResMed ventures and initiatives, the unit responsible for growing early stage businesses. In March 2013, he was appointed president Americas. Before joining us, Mr. Hollingshead spent 18 years in strategy consulting, where he worked with senior executives across a wide range of industries. From September 2008 to February 2010, he was a senior partner in the strategy and life sciences practices at Deloitte Consulting, based in San Francisco. Before that Mr. Hollingshead was managing partner, west coast for Monitor Group, a global strategy consulting firm. While at Monitor Group, Mr. Hollingshead worked in various offices around the world, and successfully launched and ran three different practices, including a panEuropean marketing strategy practice based in London. Mr. Hollingshead currently sits on the board of SleepScore Labs, a joint venture between ResMed, Pegasus Capital and Oz Media, aimed at creating a consumer marketplace for scientifically validated sleep solutions like the S by ResMed since 2020.
| Age | 57 |
| Tenure | 4 years |
| Professional Marks | Ph.D |
| Address | 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 |
| Phone | 858-836-5000 |
| Web | https://www.resmed.com |
ResMed Management Efficiency
The company has Return on Asset of 0.1119 % which means that on every $100 spent on assets, it made $0.1119 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2166 %, implying that it generated $0.2166 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to 0.13. In addition to that, Return On Capital Employed is expected to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 477.5 M, whereas Deferred Long Term Asset Charges is forecasted to decline to about 42.6 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Sanjay Prabhakaran | Hologic | N/A | |
| Karen Flynn | West Pharmaceutical Services | 55 | |
| Giuseppe Accogli | Baxter International | 53 | |
| Scott Pleau | Baxter International | 52 | |
| Nabil Shabshab | Becton Dickinson and | 51 | |
| Surindra Mann | STAAR Surgical | N/A | |
| David Hickey | Becton Dickinson and | 60 | |
| Marcus Schabacker | Baxter International | 52 | |
| Cameron Hicks | Teleflex Incorporated | 59 | |
| SueJean Lin | Alcon AG | 65 | |
| Andrew Frye | Baxter International | 59 | |
| Randal Golden | The Cooper Companies | 57 | |
| Heino Lennartz | West Pharmaceutical Services | 49 | |
| Virginia Sanzone | ICU Medical | 49 | |
| Praneet Mehrotra | Teleflex Incorporated | N/A | |
| Christopher DelOrefice | Becton Dickinson and | 52 | |
| Brian Andrews | The Cooper Companies | 45 | |
| Tom McCall | ICU Medical | 60 | |
| Ellen Strahlman | Becton Dickinson and | 59 | |
| Quintin Lai | West Pharmaceutical Services | 53 | |
| Keith Holliday | STAAR Surgical | 61 | |
Management Performance
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.11 |
ResMed Inc Leadership Team
Elected by the shareholders, the ResMed's board of directors comprises two types of representatives: ResMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ResMed. The board's role is to monitor ResMed's management team and ensure that shareholders' interests are well served. ResMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ResMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bobby Ghoshal, Chief Technology Officer, President - SaaS business | ||
| AM BE, Chair Founder | ||
| John Wareham, Independent Director | ||
| Ronald Taylor, Lead Independent Director | ||
| Michael Rider, Chief Officer | ||
| Gary Pace, Independent Director | ||
| Agnes Lee, Senior Director - Investor Relations | ||
| Vered Keisar, Chief Officer | ||
| Harjit Gill, Independent Director | ||
| Kaushik Ghoshal, Chief SaaS | ||
| Carol Burt, Independent Director | ||
| Rich Sulpizio, Independent Director | ||
| Peter Farrell, Non-Executive Chairman of the Board | ||
| Jim Hollingshead, President – sleep and respiratory care business | ||
| Don Darkin, President - Sleep-disordered Breathing Strategic Business Unit | ||
| Jack Wareham, Independent Director | ||
| Jan Witte, Independent Director | ||
| Rajwant Sodhi, President – Software as a Service Business (SaaS) | ||
| BE MBA, CEO Director | ||
| Anne Reiser, President Europe | ||
| Karen Drexler, Independent Director | ||
| AM AM, Founder Chairman | ||
| Richard McHale, President – Respiratory Care Business | ||
| Donald Darkin, President – innovation & operations | ||
| Constance Bienfait, Director Relations | ||
| Urvashi Tyagi, Chief Technology Officer | ||
| Rob Douglas, President COO | ||
| Justin Leong, President – Asia and Latin America | ||
| Christopher Roberts, Independent Director | ||
| Chris Roberts, Independent Director | ||
| Robert Douglas, President, Chief Operating Officer | ||
| YvonneKatrin Pucknat, Chief Officer | ||
| Amy Wakeham, VP Communications | ||
| Brett Sandercock, CFO and Principal Accounting Officer | ||
| Ron Taylor, Lead Independent Director | ||
| Raj Sodhi, President – Software as a Service (SaaS) Business and CTO | ||
| David Pendarvis, Chief Administrative Officer, Global General Counsel, Secretary | ||
| Richard Sulpizio, Independent Director | ||
| Michael Farrell, Chief Executive Officer, Director | ||
| Jim Ellis, Chief Officer |
ResMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ResMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 28.27 B | ||||
| Shares Outstanding | 147.09 M | ||||
| Shares Owned By Insiders | 0.81 % | ||||
| Shares Owned By Institutions | 57.23 % | ||||
| Number Of Shares Shorted | 7.89 M | ||||
| Price To Earning | 73.48 X |
Currently Active Assets on Macroaxis
When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for ResMed Stock analysis
When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is ResMed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Dividend Share 1.84 | Earnings Share 6.04 | Revenue Per Share 30.633 | Quarterly Revenue Growth 0.125 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.